CKPT Reddit Mentions | ChartExchange

**Disclosure: I am long DERM shares. This is not financial advice. Do your own due diligence.**
---
**What Is This Company?**
Journey Medical Corporation (NASDAQ: $DERM) is a commercial-stage specialty pharma company with 8 FDA-approved prescription dermatology products. This is not a pre-revenue speculative biotech — they generated **$61.9M in revenue in FY2025**, up 11.2% YoY. Their crown jewel is **Emrosi™**, an FDA-approved rosacea drug launched March 2025 and the fastest-growing asset in the portfolio.
| Metric | Value |
|---|---|
| Current Price (Apr 17) | $5.39 |
| Market Cap | $147.31M |
| Shares Outstanding | 33.26M |
| FY2025 Revenue | $61.9M |
| P/S Ratio | 2.9x |
| 52-Week Range | $4.31 – $9.55 |
---
**The Core Thesis: Emrosi™**
Emrosi is a modified-release minocycline — the only drug of its type specifically dosed for moderate-to-severe rosacea. FDA approved November 2024, commercially launched March 2025.
**In just 9 months:**
- 53,000 total Rx written in FY2025
- 126,000 annualized Rx run-rate by Q4 2025 — trajectory more than doubling YoY
- Refill ratio of **1.4x** — patients returning for chronic refills (most important metric for a maintenance drug)
- 3,500+ active prescribers across dermatology practices
- **65% of commercial lives covered** under GPO contracts (up from 29% in May 2025)
- Phase 3 data published in *JAMA Dermatology* — peer-reviewed superiority over doxycycline (current standard of care)
- Management stated **$300M global peak revenue potential**
- Phase 1 data: zero detectable effects on gut, skin, or vaginal microflora after 16 weeks — major safety advantage over older antibiotics
The US rosacea market has ~16M patients. Current options are old, generic, and inadequate. Emrosi is genuinely differentiated on both efficacy and tolerability.
**Annualized Q4 revenue run-rate from Emrosi alone: ~$35M. From zero, in 9 months.**
---
**Why Is the Stock Still Down ~43% From Its 52-Week High?**
Two reasons — both potentially temporary:
1. **Gross-to-net headwind during launch phase** — Emrosi's Q3 2025 revenue missed estimates because copay cards were subsidizing patient costs while formulary coverage was still building. Standard launch-phase dynamic, not a drug problem. Coverage has since expanded materially.
2. **Macro micro-cap selloff** — Small caps crushed across the board in 2026. DERM got dragged down despite company-specific fundamentals improving every single quarter.
---
**The Short Interest Setup**
| Metric | Value |
|---|---|
| SI % of Float | 14.77% |
| Shares Short | 4.28M |
| Days to Cover | 9.0 |
| Trend | Declining (was 4.31M prior month) |
Not a pure squeeze play — but a 9-day cover ratio combined with a May binary catalyst and a 33M share low float means any positive momentum gets amplified by forced short covering. Shorts are positioned for continued revenue misses. If Q1 2026 shows Emrosi acceleration continuing, they are wrong-footed with **9 days of average volume needed to exit**.
---
**Institutional Conviction: Wasatch Advisors Holds 10%**
On April 6, 2026, **Wasatch Advisors LP** — a $20B+ AUM small-cap growth fund with one of the best long-term track records in the space — filed Schedule 13G/A Amendment No. 2 confirming:
- **2,133,370 shares = 10.0% of DERM**
- Held as of March 31, 2026 — after the Q4 earnings drop, and after the macro selloff
- Second amendment = they have held since at least May 2025 and **never reduced**
Wasatch is known for 3–7 year holding periods and fundamental-only research. They do not take 10% positions without deep conviction. Their maintained stake at current prices is one of the strongest available signals in a stock this size.
---
**Debt Situation — Bear Case Addressed**
DERM has a $25M term loan with SWK Holdings (recently acquired by Runway Growth Finance — better capitalized, no change to loan terms).
**Critical detail:** The loan has a revenue-based deferral trigger — if FY2025 revenue exceeds $60M, all principal repayments defer until **February 2027**. DERM's FY2025 revenue was **$61.9M**. Trigger almost certainly met. DERM's $24.1M cash balance is protected from principal drain through the entire critical period including May earnings. Interest-only cost is approximately $3.4M annually — very manageable against growing revenue.
---
**Acquisition Optionality**
FBIO has a proven track record of building subsidiaries and monetizing them. In May 2025 they sold Checkpoint Therapeutics to Sun Pharma for $355M — 1.18x Checkpoint's $300M peak sales estimate, despite Checkpoint having **zero revenue** at time of sale.
DERM has $61.9M in actual revenue today and the same $300M Emrosi peak estimate.
| Scenario | EV | Per Share |
|---|---|---|
| CKPT comparable (1.18x peak + legacy) | $449M | $13.51 |
| Oncology discount -20% | $359M | $10.81 |
| Revenue premium +35% for actual sales | $607M | $18.24 |
Natural acquirers: Sun Pharma (already in derm-oncology with UNLOXCYT), Galderma, LEO Pharma, Almirall, AbbVie. DERM's 3,500+ prescriber relationships and commercial derm infrastructure have standalone strategic value to any large derm player.
---
**The May 2026 Catalyst**
Q1 2026 earnings (expected May 2026) is the single most important near-term event.
---
**12-Month Price Targets (from $5.39)**
| Scenario | Probability | Target | Return |
|---|---|---|---|
| Bear | 15% | $6.20 | +15% |
| Base | 53% | $10.71 | +99% |
| Bull | 32% | $19.06 | +254% |
| **Probability-Weighted EV** | | **$12.10** | **+125%** |
Even the bear case is positive from current price. A setup where the worst realistic outcome is still a gain is genuinely rare.
---
**Risk Factors**
- Q1 2026 revenue miss would pressure stock back toward $4.00 support
- SWK loan covenant breach risk (~10% probability) if Emrosi growth reverses significantly
- Third GPO formulary deal may not close on expected timeline
- Macro recession could continue suppressing micro-cap multiples
- Ongoing Johnson Fistel shareholder investigation (appears routine, low material impact probability)
- FBIO dilutive offering risk (significantly reduced post $205M PRV cash)
---
*I hold shares in DERM. This is my personal research and opinion only. Not financial advice. Always do your own due diligence. This post was researched and written with the assistance of Claude (Anthropic). All data points, investment thesis, and conclusions are my own.*